AUTHOR=Fang Min , Kong Ling-Yao , Ji Guang-He , Pu Feng-Lan , Su You-Zhu , Li Yu-Fei , Moore Michael , Willcox Merlin , Trill Jeanne , Hu Xiao-Yang , Liu Jian-Ping 

TITLE=Chinese medicine Phragmites communis (Lu Gen) for acute respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1242525

DOI=10.3389/fphar.2024.1242525

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Acute respiratory tract infections (ARTIs) are the most common cause of morbidity and mortality worldwide, with most people experiencing at least one episode per year. Current treatment options are mainly symptomatic therapy. Antivirals, antibiotics, and glucocorticoids are of limited benefit for most infections. Traditional Chinese medicine has shown potential benefits in the treatment of ARTIs.</p><p><bold>Objective:</bold> The objective of this study was to determine the efficacy, effectiveness, and safety of <italic>Phragmites communis Trin.</italic> (<italic>P. communis, a synonym of Phragmites australis (Cav.) Trin. ex Steud</italic>) as monotherapy or as part of an herb mixture for ARTIs.</p><p><bold>Method:</bold> Eight databases and two clinical trial registries were searched from inception to 8 February 2023 for randomized controlled trials (RCTs) evaluating any preparation involving <italic>P. communis</italic> without language restrictions. The Risk of Bias Tool 2.0 was used to assess the risk of bias of the included trials. RevMan 5.3 software was used for data analyses with effects estimated as risk ratios (RRs), mean differences (MDs), or standardized mean differences (SMDs) with 95% confidence intervals (CIs). The online GRADEpro tool was used to assess the certainty of the evidence, if available.</p><p><bold>Results:</bold> Forty-two RCTs involving 6,879 patients with ARTIs were included, with all trials investigating <italic>P. communis</italic> as part of an herbal mixture. Of the included trials, the majority (38/42) were considered high risk. Compared to the placebo, <italic>P. communis</italic> preparations improved the cure rate [RR = 1.60, 95% CI (1.13, 2.26)] and fever clearance time [MD = −2.73 h, 95% CI (−4.85, −0.61)]. Compared to usual care alone, <italic>P. communis</italic> preparations also significantly improved the cure rate [RR = 1.57, 95% CI (1.36, 1.81)] and fever clearance time [SMD = −1.24, 95% CI (−2.37, −0.11)]. <italic>P. communis</italic> preparations plus usual care compared to usual care alone increased the cure rate [RR = 1.55, 95% CI (1.35, 1.78)], shortened the fever clearance time [MD = −19.31 h, 95% CI (−33.35, −5.27)], and improved FEV1 [ MD = 0.19 L, 95% CI (0.13, 0.26)] and FVC [ MD = 0.16 L, 95% CI (0.03, 0.28)].</p><p><bold>Conclusion:</bold> Low- or very low-certainty evidence suggests that <italic>P. communis</italic> preparations may improve the cure rate of ARTIs, shorten the fever clearance time in febrile patients, and improve the pulmonary function of patients with acute exacerbation of chronic obstructive pulmonary disease or chronic bronchitis. However, these findings are inconclusive and need to be confirmed in rigorously designed trials.</p><p><bold>Systematic review registration</bold>: PROSPERO, identifier CRD42021239936</p>